Literature DB >> 21429939

Lack of impact of selective digestive decontamination on Pseudomonas aeruginosa ventilator-associated pneumonia: benchmarking the evidence base.

James C Hurley1.   

Abstract

BACKGROUND: The selective digestive decontamination (SDD) component antibiotics have activity against Pseudomonas aeruginosa, an important ventilator-associated pneumonia (VAP) isolate. Evaluating the relationship between the anti-pseudomonal activity of SDD towards its VAP prevention effect is complicated by postulated indirect effects of SDD mediated in the concurrent control groups. The objective here is to address these effects through a benchmarking analysis of the evidence base.
METHODS: Forty-eight observational studies of VAP incidence and 43 interventional studies of SDD and other methods of VAP prevention were sourced from 10 reviews. The P. aeruginosa isolate proportion (P. aeruginosa-IP) data were summarized by meta-analysis using random effects methods. The mode of VAP diagnosis, proportion of trauma admissions and the intervention method under study were examined in meta-regression models as potential group-level predictors of P. aeruginosa-IP.
RESULTS: The mean P. aeruginosa-IP derived from the observational studies (the benchmark) is 22.3% [95% confidence interval (CI) 19.8%-25.2%] versus 19.6% (95% CI 15.6%-24.4%) and 20.8% (95% CI 14.6%-28.5%) for concurrent control groups and intervention groups of SDD studies, respectively. In the meta-regression models, the proportion of trauma admissions is negatively correlated with P. aeruginosa-IP, whereas membership of neither a concurrent control nor intervention group of an SDD study is negatively correlated.
CONCLUSIONS: There is no evidence for either direct or indirect effects of SDD on P. aeruginosa-IP that could account for the profound effects of SDD on VAP incidence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21429939     DOI: 10.1093/jac/dkr112

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  The perfidious effect of topical placebo: calibration of Staphylococcus aureus ventilator-associated pneumonia incidence within selective digestive decontamination studies versus the broader evidence base.

Authors:  James C Hurley
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

2.  A meta-analysis of the proportion of animal Salmonella isolates resistant to drugs used against human salmonellosis in Ethiopia.

Authors:  Getachew Tadesse
Journal:  BMC Infect Dis       Date:  2015-02-21       Impact factor: 3.090

3.  A meta-analysis of the prevalence of Toxoplasma gondii in animals and humans in Ethiopia.

Authors:  Endrias Zewdu Gebremedhin; Getachew Tadesse
Journal:  Parasit Vectors       Date:  2015-05-28       Impact factor: 3.876

Review 4.  Topical antibiotics as a major contextual hazard toward bacteremia within selective digestive decontamination studies: a meta-analysis.

Authors:  James C Hurley
Journal:  BMC Infect Dis       Date:  2014-12-31       Impact factor: 3.090

5.  A meta-analysis of the prevalence of Salmonella in food animals in Ethiopia.

Authors:  Getachew Tadesse; Tesfaye S Tessema
Journal:  BMC Microbiol       Date:  2014-11-15       Impact factor: 3.605

6.  Prevalence of Salmonella in raw animal products in Ethiopia: a meta-analysis.

Authors:  Getachew Tadesse; Endrias Zewdu Gebremedhin
Journal:  BMC Res Notes       Date:  2015-04-21

Review 7.  Prevalence of human Salmonellosis in Ethiopia: a systematic review and meta-analysis.

Authors:  Getachew Tadesse
Journal:  BMC Infect Dis       Date:  2014-02-19       Impact factor: 3.090

8.  A meta-analysis of the proportion of antimicrobial resistant human Salmonella isolates in Ethiopia.

Authors:  Getachew Tadesse
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-12       Impact factor: 2.483

9.  Candida-Acinetobacter-Pseudomonas Interaction Modelled within 286 ICU Infection Prevention Studies.

Authors:  James C Hurley
Journal:  J Fungi (Basel)       Date:  2020-10-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.